Thickening of the lining of the uterus. 
Most cases of endometrial hyperplasia result from high levels of estrogens, combined with insufficient levels of the progesterone-like hormones which ordinarily counteract estrogen's proliferative effects on this tissue. This may occur in a number of settings, including obesity, polycystic ovary syndrome, estrogen producing tumours (e.g. granulosa cell tumour) and certain formulations of estrogen replacement therapy. Endometrial hyperplasia is a significant risk factor for the development or even coexistence of endometrial cancer, so careful monitoring and treatment of women with this disorder is essential.
Like other hyperplastic disorders, endometrial hyperplasia initially represents a physiological response of endometrial tissue to the growth-promoting actions of estrogen. However, the gland-forming cells of a hyperplastic endometrium may also undergo changes over time which predispose them to cancerous transformation. Several histopathology subtypes of endometrial hyperplasia are recognizable to the pathologist, with different therapeutic and prognostic implications.
Two different systems are commonly used to classify EH, the World Health Organization (WHO) and the endometrial intraepithelial neoplasia (EIN) (Tab. 1). The WHO classification system, which is the most commonly recognized system, use cellular complexity, crowding of the endometrial gland and the presence of cytological atypia to categorize pathologies as simple or complex hyperplasia, with or without atypia. The complexity of the WHO classification system has prompted improvement of an alternative system, the EIN. The EIN classifies EH as either benign or hyperplasia, and includes additional EIN and cancer classifications. Cases are categorized as EIN based on architectural gland crowding, altered cytology and maximum linear dimension of the lesion exceeding 1 mm, while excluding cancer and mimics. The EIN classification system can easily be applied to routine H&E stained sections and is more reproducible, helping clinicians to select treatment options.
However, the most commonly used classification system for endometrial hyperplasia is the World Health Organization system, which has four categories:
1. simple hyperplasia without atypia 2. complex hyperplasia without atypia 3. simple atypical hyperplasia 4. complex atypical hyperplasia (1. + 2.) Endometrial hyperplasia (simple or complex) -Irregularity and cystic expansion of glands (simple) or crowding and budding of glands (complex) without worrisome changes in the appearance of individual gland cells. In one study, 1.6% of patients diagnosed with these abnormalities eventually developed endometrial cancer.
(3. + 4.) Atypical endometrial hyperplasia (simple or complex) -Simple or complex architectural changes, with worrisome (atypical) changes in gland cells, including cell stratification, tufting, loss of nuclear polarity, enlarged nuclei, and an increase in mitotic activity. These changes are similar to those seen in true cancer cells, but atypical hyperplasia does not show invasion into the connective tissues, the defining characteristic of cancer. The previously mentioned study found that 22% of patients with atypical hyperplasia eventually developed cancer.
Diagnosis of endometrial hyperplasia can be made by endometrial biopsy which is done in the office setting or through curettage of the uterine cavity to obtain endometrial tissue for histopathologic analysis. A workup for endometrial disease may be prompted by abnormal uterine bleeding, or the presence of atypical glandular cells on a pap smear.
Although there is no bona fide treatment for EH, most current guidelines recommend hormone therapies (including use of progestin, gonadotropin-releasing hormone (GnRH) or its analogues or their combination) or surgical treatment (Pic. 1). The selection criteria for treatment options are based on patient age, health, the presence of cytologic-atypia and fertility status (Pic. 2). EH without atypia responds well to progestins.
Associated diseases
anemia polycystic ovary syndrome (PCOS) -endocrine and metabolic abnormalities that are left untreated in women with PCOS often develop into atypical endometrial hyperplasia and endometrial dysfunction-induced infertility endometrial carcinoma -endometrial hyperplasia is a significant risk factor for the development or even co-existence of endometrial cancer, so careful monitoring and treatment of women with this disorder is essential
Complications
Endometrial hyperplasia has a high risk for malignant transformation and relapses.
Risk factors
Since EH is a precursor to cancer, all risk-factors of EC could be related to EH (Tab. 2). metabolic syndrome postmenopause during perimenopause insulin resistance type II diabetes polycystic ovary syndrome (PCOS) diabetes thyroid disease women over age 35 never being pregnant obesity smoker  Impact on fertility Many women are able to become pregnant with endometrial overgrowth, but it is major that you talk to your doctor regarding therapy options that thrifty to your fertility. In reality, studies have shown that about 30% of women who have endometrial overgrowth and choose for these types of treatments are able to have a live birth.
However, it is possible that women who have forward stages of this disease will find that their ability to become pregnant is complete stopped because of the treatments that are required to repair the issue. For this reason, it is relevant that you seek medical attention as soon as possible when you have been diagnosed with endometrial overgrowth.
Surgical methods (hysterectomy, hysteroscopic endometrial resection/ablation) lead to the removal or disruption of the endometrium and can cause infertility.
 Prevention
The primary role of progestin in postmenopausal estrogen therapy is endometrial protection to prevent hyperplasia. Eat a healthy diet.
 Symptoms acne abnormal vaginal bleeding dryness of the vagina excessive growth of body hair menorrhagia hot flashes amenorrhea (absence of menstrual periods) mood swings pain during sexual intercourse rapid heart rate (tachycardia) severe fatigue tenderness of the vagina anovulatory periods (menstrual cycles without ovulation)  Therapies  Self therapy Acupuncture EH is from unbalance of hormones. Acupuncture try to treat unbalance of hormones and herbs may help causes of unbalance of hormones.
 Conventional medicine Pharmacotherapy

Progestin
Oral use of progestin, such as megestrol acetate (MA), and medroxyprogesterone acetate (MPA) is the most commonly used method with various regimens available for treatment of endometrial hyperplasia (EH). Nonetheless, the response rate is unsatisfactory, especially in atypical EH (approximately 70%). Progestin therapy may be continued or hysterectomy performed in cases of no response. Moreover, oral progestins are associated with poor compliance and systemic side effects that may limit overall efficacy. Different types of progestins and their doses in clinical use for the treatment of EH are shown in (Tab. 3 and 4).
Metformin
Metformin, insulin sensitizer, decreases insulin resistance by the inhibition of hepatic gluconeogenesis. Metformin not only lowers insulin levels and can also provide benefits by decreasing body weight, which diminishes the peripheral conversion of androgen. In addition, a low body index is related to a high resolution rate in EH patients with progestin treatment. Therefore, metformin may be proposed as an alternative agent for treatment of EH, especially for patients who have progestin resistance or other metabolic disorders.
Surgical therapy
Hysterectomy
Endometrial hyperplasia (EH), especially in the presence of atypia, has a strong tendency to the development of endometrial carcinoma. In this respect, hysterectomy is a preferred treatment for atypical EH. However, for young patient who desire to preserve their fertility or for patients not selected for surgery, conservative treatments using progestin are widely accepted as a treatment option.
 Assisted reproduction
Conservative treatment with high-dose progesterone for endometrial hyperplasia and well-differentiated early-stage adenocarcinoma followed by assisted reproductive technologies (IVF-ICSI) is an appropriate means for achieving pregnancy. If all efforts to conceive and carry a pregnancy to full-term fails, surrogacy may be considered.
